Brazil, US Resume Tariff Talks as Trade Tensions Persist 
Gold Prices Slide as Iran Conflict Fuels Fed Rate Hike Bets 
Asian Currencies Mixed as Yen Nears 160, Oil Surges 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Asian Stocks Tumble as Oil Surge Fuels Rate Hike Fears 
CIA-Linked Investor Helped Quantum Systems Expand in US 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
US Strikes Iran IRGC Targets as Conflict Escalates 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
France Targets Shein, Temu With Fast-Fashion Fees 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Add as a preferred source on Google
Samsung Biologics and Biogen, an American biotechnology company, based in Cambridge, Massachusetts, signed a deal for the transfer of stake in Samsung Boiepis. The South Korean biotech firm headquartered in Songdo, Incheon, is buying all of Biogen’s stake in the biopharma company.
Samsung Bioepis was formed in 2012 via a joint venture between Samsung Biologics and Biogen. The latter owned a 15% stake at first, and in 2018, the percentage was increased to 50% as it extended its controlling rights in the company.
As per The Korea Herald, the acquisition of Biogen’s stake is predicted to help boost Samsung Biologic’s competitiveness in the global bio market. The value of the deal is ₩2.7 trillion or around $2.3 billion.
The total shares acquired are 10,341,852 units, and Samsung Biologics stated that the company’s board of directors approved the transaction. The payments for the stakes are set to be made in installments and will be paid over the next two years.
The full ownership of the shares will take effect once the first payment of $1 billion is completed. It was revealed that it was Biogen that forwarded a request for the buyout deal. Despite the acquisition, both companies said they would continue to work as close partners.
“We are thankful to Samsung Biologics for a productive collaboration since 2012,” Biogen’s chief executive officer, Michel Vounatsos, said in a press release. “We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen.”
With the transaction, Samsung Biologics Co. will take over and be in full control of Samsung Bioepis Co. since the deal is for the entire holdings of Biogen’s shares. Pulse News reported that the transfer of shares is set to take place on April 30, 2022.
Meanwhile, Samsung Bioepis is currently developing five biosimilar drugs that it will be launching worldwide. One of them is just waiting for approval and ready for marketing. The four other drugs are in the third phase of clinical trials. Two of the medicines are for oncology, and three are formulated for autoimmune.
